Cargando…
The next forum for unraveling FDA off-label marketing rules: State and federal legislatures
In a Guest Editorial, Aaron S. Kesselheim and Michael S. Sinha show how federal and state legislation to allow promotion of drugs for non-approved uses threatens to undermine the FDA's public health mission.
Autores principales: | Sinha, Michael S., Kesselheim, Aaron S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940176/ https://www.ncbi.nlm.nih.gov/pubmed/29738523 http://dx.doi.org/10.1371/journal.pmed.1002564 |
Ejemplares similares
-
The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine
por: Wang, Bo, et al.
Publicado: (2017) -
The State Legislature and Vivisection
Publicado: (1875) -
The Intersection of Antimicrobial Stewardship, the Pharmaceutical Industry, and the Federal Legislature
por: Gregory, Eric, et al.
Publicado: (2022) -
Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A
Retrospective Analysis of Whistleblower Complaints
por: Kesselheim, Aaron S., et al.
Publicado: (2011) -
Inebriety and the Legislature
Publicado: (1892)